1-(18F)Fluoranyl-3-[[2-[(E)-4-[6-(methylamino)pyridin-3-yl]but-1-en-3-ynyl]-1,3-benzothiazol-6-yl]oxy]propan-2-ol
Healthy Volunteers
APRINOIA Therapeutics, LLCSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 81/ 100
Competitive context
64 Active assets in the Healthy Volunteers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Semaglutide Novo Nordisk A/S | Phase 4 | BB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE National Institute of Mental Health (NIMH) | Phase 4 | BB |
Alpha-1-Proteinase Inhibitor Baxalta now part of Shire | Phase 4 | BB |
DULAGLUTIDE Novo Nordisk A/S | Phase 4 | BB |
NORMAL HUMAN SERUM ALBUMIN Baxalta now part of Shire | Phase 4 | BB |
View all 50 →
Same molecule, other indications
1-(18F)Fluoranyl-3-[[2-[(E)-4-[6-(methylamino)pyridin-3-yl]but-1-en-3-ynyl]-1,3-benzothiazol-6-yl]oxy]propan-2-ol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →